<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730947</url>
  </required_header>
  <id_info>
    <org_study_id>20-005646</org_study_id>
    <nct_id>NCT04730947</nct_id>
  </id_info>
  <brief_title>Dapagliflozin (DAPA) Effects in HFpEF</brief_title>
  <official_title>Evaluation of the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction (CAMEO-DAPA): A Phase II, Prospective, Double-Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with Dapagliflozin (DAPA) for 6&#xD;
      months will improve pulmonary capillary wedge pressure (PCWP) during exercise in heart&#xD;
      failure/preserved ejection fraction (HFpEF) and improve cardiac metabolism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">July 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 21, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary Capillary Wedge Pressure (PCWP)</measure>
    <time_frame>Baseline, 7 months</time_frame>
    <description>Change in the PCWP during exercise reported in mmHg</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with HFpEF will take the study drug dapagliflozin daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with HFpEF will take a placebo daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>10 mg orally once a day</description>
    <arm_group_label>Dapagliflozin Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent prior to any study specific procedures.&#xD;
&#xD;
          -  Male or female.&#xD;
&#xD;
          -  Symptoms of dyspnea (NYHA II-III) with no non-cardiac or ischemia explanation.&#xD;
&#xD;
          -  EF ≥ 50% + BMI ≥ 30 kg/m^2&#xD;
&#xD;
          -  Elevated pulmonary capillary wedge pressure (PCWP) during exercise (≥ 25 mmHg)&#xD;
             ascertained at Visit 1. Patients that have consented to study procedures but do not&#xD;
             meet this invasive criterion will be considered as screen failures and will not be&#xD;
             randomized .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type I diabetes.&#xD;
&#xD;
          -  Type II diabetes with poor control (HgbA1C ≥ 10%).&#xD;
&#xD;
          -  Recent hospitalization (&lt; 30 days) or revasculariation (&lt; 90 days).&#xD;
&#xD;
          -  Primary cardiomyopathy (such as amyloid).&#xD;
&#xD;
          -  Constrictive pericarditis.&#xD;
&#xD;
          -  Dyspea due to primary lung disease or myoardial ischemia in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Severe anemia (hemoglobin &lt; 9gm/dl.&#xD;
&#xD;
          -  Significant left-sided valvular heart disease (&gt; mild stenosis, &gt; moderate&#xD;
             regurgitation),&#xD;
&#xD;
          -  Severe kidney disease (estimated GFR &lt; 30) or liver disease,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry A Borlaug</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda M Braun</last_name>
      <phone>507-293-2762</phone>
      <email>braun.amanda@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Peter J Mathiason</last_name>
      <phone>507-255-0473</phone>
      <email>mathiason.peter@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Barry Borlaug</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

